CTRI/2018/10/016022招募中未知
A multicenter, randomized, open-label, two-way crossover study to assess inspiratory flow profiles generated with medication-free CIPLA Dry Powder Inhaler and Seretide Accuhaler in healthy adult subjects, adult patients with moderate to severe asthma, adult patients with moderate to severe chronic obstructive pulmonary disease and children with asthma
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- Cipla Ltd
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Healthy adult subjects: 1. Male and female healthy adult subjects of any ethnic origin, aged from 18 to 55 years (inclusive).2. Signed and dated written informed consent.3. Forced vital capacity (FVC) >80%, Peak Expiratory Flow Rate (PEFR) >80%, Forced expiratory volume in one second (FEV1) >80% of that predicted by the European Coal and Steel Community (ECSC) formulae (confirmed by spirometry test), a FVC >80% and a FEV1/FVC ratio >= 0.75.4. Oxygen saturation >= 95 % .5. Subjects who have not taken any drugs within 2 days prior to screening.6. Female subjects of childbearing potential must use an adequate method of contraception (e.g., hormonal birth control, intrauterine device, barrier method plus a spermicidal agent) during the study.
- •7. Subjects who are non-smokers or those who are ex-smokers and have less than a 10 pack-year history of smoking and have not consumed tobacco or tobacco containing products for at least 12 months prior to screening and who agree to abstain from the same during the study.
- •Children with asthma
- •1. Male and female children of any ethnic origin, aged from 4 to <18 years .2. Ability and willingness to participate in the study.
- •3. Informed Consent, signed and dated by parents (or legal representatives) and documented assent by the child.4. Diagnosis of asthma based on physician diagnosis/PEFR reversibility/spirometry reversibility/Clinical history and symptoms of asthma for minimum of 6 months prior to screening.5. Treatment with any asthma medication (including inhaled corticosteroid) at a constant dosage during four (4) weeks prior to inclusion in study
- •6. Non-smoker
- •Adult patients with asthma
- •1. Male and female subjects of any ethnic origin, aged 18 years or more.2. Signed and dated written informed consent.3. Established diagnosis of asthma (according to GINA 2003 asthma severity based on lung physiology) for at least 6 months prior to Screening visit and who meet the following criteria:- Pre-bronchodilator FEV1 between 60 % and 80 % (not inclusive) of the predicted value for age, height and sex using the form ula of the European Coal and Steel Community (ECSC) using appropriate correction factors for race
- •OR - Pre-bronchodilator FEV1 of <= 60% of the predicted value for age, height and sex using the formula of the European Coal and Steel Community (ECSC) using appropriate correction factors for race AND - Historic evidence of reversibility performed as per ATS guideline of within 12 months before screening. If historic evidence not available, reversibility, defined as an increase in FEV1 of >= 12 % and >= 200 mL from baseline within 15-30 minutes following intake of 400 mcg salbutamol, administered from an Metered Dose Inhaler, as measured during Screening.4.Regular treatment with inhaled asthma medication at a constant dosage during the last four (4) weeks prior to Screening (Visit 1).5.Female subjects of childbearing potential must use an adequate method of contraception (e.g., hormonal birth control, intrauterine device, barrier method plus a spermicidal agent) during the entire study.
排除标准
- •1. Acute exacerbation of bronchial asthma or COPD or hospitalization/emergency room visits due to asthma/COPD exacerbation within the last 2 months prior to study participation.
- •2. Requirement for oral/injectable steroid therapy due to unstable disease within the last 2 months prior to screening.
- •3. Significant lung/airway diseases other than the asthma or COPD diagnosis for each of the subject groups.
- •4. Surgery of the respiratory tract/lung or significant deformity (e.g., lung, conducting airways, thorax or vertebral column deformities) that may cause persistent airflow limitation or altered lung volumes.
- •5. Salbutamol intolerance or contraindication to salbutamol (for adult subjects with asthma or COPD).
- •6. Significant acute respiratory infections within the last 4 weeks or chronic viral, bacterial or fungal airway infections.
- •7. Other chronic or clinically relevant acute infections.
- •8. Neurological diseases affecting the neuro-muscular function or performance of respiratory muscles, e.g., such as Myasthenia Gravis or Amyotrophic Lateral Sclerosis.
- •9. Any major chronic illness including but not limited to a diagnosis of non-skin cancer, cystic fibrosis, bronchiectasis, α-1 anti-trypsin deficiency, myelomeningocele, sickle cell anemia, endocrine disease, congenital heart disease, unstable arrhythmia, congestive heart failure, stroke, severe hypertension, uncontrolled insulin-dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, significant neurodevelopmental delay or behavioral disorders (excluding mild attention deficit hyperactivity disorder
- •10. History of diaphragm dysfunctions, diaphragm hernia or surgery.
- •11. Drug or alcohol abuse which would interfere with the subjectâ??s compliance.
- •12. Employee of study site, or spouse/partner or relative of an investigator or study staff.
- •13. Anticipated non-availability for study visits/procedures.
- •14. Surgery that can be considered as a planned intervention (e.g., cataract surgery) within the entire study period.
- •15. Obvious mental or physical incapacity to follow study procedures and investigator instructions adequately or to correctly practice inhalation and to use devices for inhalation.
- •16. Pregnant or nursing women.
- •17. Severe concomitant disease which may have an impact on the study participation as assessed by investigator
- •18. Patients with any history of premature birth less than 33 weeks gestation or significant level of respiratory care including mechanical ventilation required as neonate affecting the respiratory tract or chronic lung diseases, which in the opinion of the investigator or designated study personnel at site may interfere with the study evaluation or optimal participation in the study
- •19. Subject unable to perform acceptable inhalation manoeuvers during the training on Cipla DPI device at screening visit
研究者
相似试验
已完成
不适用
The clinical trial to assess inspiratory flow profiles generated with medication-free CIPLA dry Inhaler and Seretide Accuhaler in moderate to severe COPD patientsCTRI/2021/01/030677Cipla Ltd32
进行中（未招募）
不适用
A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar® 100 µg bd delivered via a metered dose inhaler (MDI) (TEVA UK Ltd) with a reference beclometasone formulation via a reference MDI in children with mild to moderate asthmaShort-term lower leg growth rate in children with documented mild to moderate asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-007455-14-DKTEVA UK Ltd
进行中（未招募）
1 期
A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime.(PREDICTIVE-BMI study) - PREDICTIVE-BMI studyType 2 diabetesMedDRA version: 7.0Level: PTClassification code 10049746EUCTR2005-000976-42-ESovo Nordisk Pharma S.A.
招募中
1 期
Bioavailability study between Bortezomib for Injection 3.5 mg/0.2 mL and VELCADE 3.5 mg powder for solution for injection at a dose of 1.3 mg/m2CTRI/2020/06/025971Shilpa Medicare Limited
已完成
不适用
Bioavailability study of Bortezomib for Injection 3.5 mg/vial in patients with Multiple MyelomaCTRI/2019/03/018107Shilpa Medicare Limited6